Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a ... 7thSpace Interactive (press release) Everolimus and sunitinib have been approved for the treatment advanced pancreatic neuroendocrine tumors, but have not been compared to each other in a randomized trial and have not demonstrated prolonged overall survival compared to placebo. |
